Eisai Launches Hepatitis Drug Clevudine In The Philippines
This article was originally published in PharmAsia News
Executive Summary
Manila-based Eisai subsidiary Hi-Eisai Pharmaceutical launched Revovir (clevudine) Feb. 24 in the Philippines for patients with chronic hepatitis B